Author:
Selen Arzu,Cruañes Maria T.,Müllertz Anette,Dickinson Paul A.,Cook Jack A.,Polli James E.,Kesisoglou Filippos,Crison John,Johnson Kevin C.,Muirhead Gordon T.,Schofield Timothy,Tsong Yi
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Guidance for Industry Q8(R2) Pharmaceutical development, 2009 (ICH Q8 (R2)).
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073507.pdf
.
2. Gray VA. Meeting report: University of Wisconsin/AAPS/FDA Workshop Applied Biopharmaceutics and Quality by Design for Dissolution/Release Specification Setting: Product Quality for Patient Benefit. Dissolution Technologies. 2009;16(4):35–9.
3. Dickinson PA, Lee WW, Stott PW, Townsend AI, Smart JP, Ghahramani P, et al. Clinical relevance of dissolution testing in quality by design. AAPS J. 2008;10(2):380–90.
4. Müllertz A. Biorelevant dissolution media, biotechnology. Pharmaceutical aspects. Arlington: AAPS; 2007. p. 151–77.
5. Benet LZ, Wu CY. Using a biopharmaceutics drug disposition classification system to predict bioavailability and elimination characteristics of new molecular entities. Somerset: NJDMDG; 2006.
Cited by
28 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献